( ficantly lower than the rate in the bar...)Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,,,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,,,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,,,Disease,Health

ficantly lower than the rate in the bare metal stent arm of the ARTS I Study (1.3 percent versus 7.1 percent, respectively; p = 0.018). Three-year stent thrombosis comparisons with the BMS arm were not possible, as the ARTS I Study did not track stent thrombosis rates beyond 30 days. The cumulative rates of definite stent thrombosis for the CYPHER(R) Stent at three-year follow-up in the overall ARTS II Study patient population was 3.3 percent. Investigators did not find significant differences in the stent thrombosis rates between the ARTS II diabetic and non-diabetic patients using any of the ARC definitions.

The CYPHER(R) Stent does not have an approved indication in the United States for diabetic patients or patients with multivessel coronary disease.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at

Page: 1 2 3 4
Related medicine technology :

1. Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
4. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
5. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
8. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
9. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
10. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
11. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials